文献速递心境障碍精神分裂症与精神病性障碍

犬尿氨酸通路在重性抑郁障碍、双相障碍和精神分裂症中的荟萃分析

The kynurenine pathway in major depressive disorder, bipolar disorder, and schizophrenia: a meta-analysis of 101 studies.
PubMed 文献 · Mol Psychiatry · 2020-11-23

该荟萃分析纳入101项研究共10912名参与者,比较重性抑郁障碍(MDD)、双相障碍(BD)和精神分裂症(SZ)患者与对照者的犬尿氨酸通路代谢物差异。结果显示色氨酸和犬尿氨酸在三种障碍中均降低, mood障碍中犬尿喹啉酸及犬尿喹啉酸/喹啉酸比值降低而SZ中犬尿喹啉酸未变,提示色氨酸代谢从血清素向犬尿氨酸通路偏移且mood障碍与SZ模式不同。

要点

  • 色氨酸和犬尿氨酸在MDD、BD和SZ中均降低。
  • 犬尿喹啉酸及犬尿喹啉酸/喹啉酸比值在mood障碍中降低,SZ中犬尿喹啉酸未变。
  • MDD和SZ中犬尿氨酸/色氨酸比值升高,犬尿喹啉酸/犬尿氨酸比值降低。

核心结论

  • 色氨酸代谢从血清素向犬尿氨酸通路偏移见于MDD、BD和SZ。
  • mood障碍与SZ存在差异模式:mood障碍偏好生成潜在神经毒性喹啉酸而非神经保护性犬尿喹啉酸,SZ无此偏好。

研究设计与样本

  • 系统检索电子数据库,纳入评估犬尿氨酸通路代谢物(色氨酸、犬尿氨酸、犬尿喹啉酸、喹啉酸、3-羟基犬尿氨酸及相关比值)的研究。
  • 共纳入101项研究、10912名参与者,比较MDD、BD或SZ患者与对照者的代谢物浓度差异,效应量以Hedges' g及95%置信区间表示。

主要发现

  • 色氨酸和犬尿氨酸在MDD、BD和SZ中均降低。
  • 犬尿喹啉酸及犬尿喹啉酸/喹啉酸比值在mood障碍(MDD和BD)中降低,而SZ中犬尿喹啉酸未改变。
  • 犬尿喹啉酸/3-羟基犬尿氨酸比值在MDD中降低但SZ中未降低。
  • 犬尿喹啉酸/犬尿氨酸比值在MDD和SZ中降低,犬尿氨酸/色氨酸比值在MDD和SZ中升高。

临床怎么用

  • 犬尿氨酸通路代谢物可能作为MDD、BD和SZ的潜在生物标志物,但需进一步验证。
  • mood障碍与SZ的犬尿氨酸代谢模式差异或有助于鉴别诊断及靶向治疗开发。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The importance of tryptophan as a precursor for neuroactive compounds has long been acknowledged. The metabolism of tryptophan along the kynurenine pathway and its involvement in mental disorders is an emerging area in psychiatry. We performed a meta-analysis to examine the differences in kynurenine metabolites in major depressive disorder (MDD), bipolar disorder (BD), and schizophrenia (SZ). Electronic databases were searched for studies that assessed metabolites involved in the kynurenine pathway (tryptophan, kynurenine, kynurenic acid, quinolinic acid, 3-hydroxykynurenine, and their associate ratios) in people with MDD, SZ, or BD, compared to controls. We computed the difference in metabolite concentrations between people with MDD, BD, or SZ, and controls, presented as Hedges' g with 95% confidence intervals. A total of 101 studies with 10,912 participants were included. Tryptophan and kynurenine are decreased across MDD, BD, and SZ; kynurenic acid and the kynurenic acid to quinolinic acid ratio are decreased in mood disorders (i.e., MDD and BD), whereas kynurenic acid is not altered in SZ; kynurenic acid to 3-hydroxykynurenine ratio is decreased in MDD but not SZ. Kynurenic acid to kynurenine ratio is decreased in MDD and SZ, and the kynurenine to tryptophan ratio is increased in MDD and SZ. Our results suggest that there is a shift in the tryptophan metabolism from serotonin to the kynurenine pathway, across these psychiatric disorders. In addition, a differential pattern exists between mood disorders and SZ, with a preferential metabolism of kynurenine to the potentially neurotoxic quinolinic acid instead of the neuroprotective kynurenic acid in mood disorders but not in SZ.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Marx W, McGuinness AJ, Rocks T, et al. The kynurenine pathway in major depressive disorder, bipolar disorder, and schizophrenia: a meta-analysis of 101 studies. Mol Psychiatry. 2020. PMID: 33230205. doi:10.1038/s41380-020-00951-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。